Please Wait.....
Report
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
Market Research Report I 2023-09-05 I 180 Pages I BCC Research
Description
Report Scope:
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.
This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.
Report Includes:
- 34 data tables and 34 additional tables
- A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
- Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
- Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
- Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
- Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
- Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
- Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
- Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
- Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi
Executive Summary
Summary:
Neurological disorders are surging; this trend is particularly noticeable in syndromes associated with progressive ataxia and weakness disorders, such as Friedreich's ataxia, spinocerebellar ataxia and muscular dystrophy. The necessity for effective treatments has intensified as more individuals are affected by these conditions. Friedreich's ataxia, in particular, stands out as the most common form of hereditary ataxia, originating from genetic factors, impacting at least 1 in every 50,000 individuals. According to the National MS Society, multiple sclerosis (MS) has a considerable presence in the United States, with an estimated one million people living with the condition. Society also reports approximately 25,000 new cases of MS diagnosed annually. As patients and healthcare professionals become more aware of these disorders, there is a growing demand for therapeutic interventions to address the challenges these debilitating conditions pose.
Key players in the global market for treatment for syndromes of progressive ataxia and weakness disorders are focused on authorizations and launches of innovative products to develop the portfolio. The product portfolio has a number of drugs used to treat multiple sclerosis, amyotrophic lateral sclerosis and hereditary neuropathies. These drugs are Kesimpta (ofatumumab), Gilenya, Exforge and Zolgensma (onasemnogene abeparvovec), with sales of $REDACTED million, $REDACTED million, $REDACTED million and $REDACTED million, in 2022, respectively. The FDA approved Skyclarys (omaveloxolone) in Feb. 2023; it is the first treatment for Friedreich's ataxia, a rare inherited degenerative disease that damages the nervous system, characterized by impaired coordination and walking.
The market has seen strategic collaborations between pharmaceutical and product-development counterparts and thus some impressive candidates may hit the market in two to four years. Penetration is also being made into emerging markets, and more European markets are opening up. The global market for progressive ataxia and weakness disorders drugs is valued at approximately $REDACTED billion in 2022 and is forecasted to grow at a CAGR of REDACTED% to reach a value of $REDACTED billion through 2028. The major players in the market are Novartis AG, Pfizer, Sanofi, GlaxoSmithKline, Roche Holding Ltd., Merck & Co., Takeda Pharmaceuticals Ltd. and Abbott Laboratories.
Neurodegenerative diseases are primarily categorized as dementia, movement disorders, progressive ataxias and weaknesses. This report intends to present a detailed analysis of the global syndromes of progressive ataxia syndromes. It studies the drug and therapy markets treating those disorders that bring progressive weakness and affect the brain and spinal cord. This report segments the market based on technology, diseases, region and distributive channel. Based on the technology, the market is segmented into small molecules, monoclonal antibodies and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases, and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. MS was the major market contributor. The market for progressive ataxia, which is growing at a CAGR of REDACTED%, is very small compared to that of progressive weakness syndromes. Based on region, the market is segmented as North America, Europe, Asia-Pacific and Rest of the World. The North American market had the highest share, followed by Europe. This leadership role is due to increasing prevalence, rising awareness, early diagnosis, the presence of major players, government initiatives, funding and good healthcare infrastructure.
Table of Contents
Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Overview
Chapter 3 Market Overview
Introduction
Definitions
Neurons
Central Nervous System
Brain
Spinal Cord
Neurotransmitters
Classification
Progressive Ataxia and Weakness Disorders
Friedreich's Ataxia
Gertsmann-Straussler-Scheinker Disease
Machado-Joseph Disease/SCA3
Amyotrophic Lateral Sclerosis
Hereditary Spastic Paraplegia
Hereditary Neuropathies
Multiple Sclerosis
Diagnostic Tests for Progressive Ataxia and Weakness Disorders
Diagnostic Tests for Multiple Sclerosis
Diagnostic Tests for Amyotrophic Lateral Sclerosis
Diagnostic Tests for Friedreich's Ataxia
Diagnostic Tests for Machado-Joseph Disease
Diagnostic Tests for Hereditary Spastic Paraplegia
Diagnostic Tests for Hereditary Neuropathies
Chapter 4 Market Dynamics
Introduction
Market Drivers
Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
Technological Advancements and Product Launch
Increasing Expenditures for Health Care
Rise in Alcohol and Drug Use
Market Barriers
Barriers to R&D for Progressive Ataxia
Diagnostic Challenges
Opportunities
Advancements in Research and Technology
Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders
Chapter 5 Market Breakdown by Type and Technology
Introduction
Market by Type
Market Overview
Market Revenue
Market by Technology
Market Overview
Market Revenue
Small Molecule
Market Overview
Market Revenue
Monoclonal Antibody
Market Overview
Market Revenue
Others
Biomarkers
Gene Therapy
Stem Cell
Market Overview
Market Revenue
Chapter 6 Market Breakdown by Disease
Overview
Market Revenue
Market by Progressive Ataxia Diseases Type
Friedreich's Ataxia
Market Revenue
Machado-Joseph disease (MJD)/SCA3
Market Revenue
Gertsmann-Straussler-Scheinker Disease
Market Revenue
Market by Disease Type
Amyotrophic Lateral Sclerosis
Progressive Bulbar Palsy
Hereditary Spastic Paraplegia
Hereditary Neuropathies (HNs)
Multiple Sclerosis (MS)
Chapter 7 Market Breakdown by Region
Introduction
North America
The U.S.
Canada
Europe
The UK
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Market Breakdown by Distribution Channel
Introduction
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Chapter 9 Emerging Technologies and Developments
Introduction
Emerging Technology
Stem Cell Therapy
Gene Therapy
Biomarkers
Nasal Spray for MS
Disease-modifying Therapies
RNA-based Therapies
Conclusion
Chapter 10 ESG Development
Introduction
ESG Investments by Key Players
Consumer Attitudes Towards ESG
Conclusion
Chapter 11 Patent Analysis
Patent Analysis by Year
Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape
Introduction
Mergers, Acquisitions and Collaborations
Strategic Initiatives
Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs
Chapter 13 Company Profiles
ABBOTT LABORATORIES
ACORDA THERAPEUTICS INC.
AMERICAN REGENT INC.
APOTEX INC.
APOTHECA INC.
ASTELLAS PHARMA INC.
ASTRAZENECA GMBH
BAXTER INTERNATIONAL INC.
BRISTOL-MYERS SQUIBB
EISAI CO. LTD.
ELI LILLY AND COMPANY
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GLENMARK LIFE SCIENCES
JOHNSON & JOHNSON
MERCK KGAA
NOVARTIS AG
PFIZER INC.
ROCHE HOLDING LTD.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 14 Appendix: Abbreviations
List of Tables
Summary Table A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
Summary Table B : Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
Table 1 : Classification, by Primary Dysfunction
Table 2 : Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
Table 3 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
Table 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
Table 5 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 6 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 7 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 8 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
Table 9 : Global Market for Friedreich's Ataxia Drugs, by Region, Through 2028
Table 10 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028
Table 11 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028
Table 12 : Latest FDA Approvals for Amyotrophic Lateral Sclerosis
Table 13 : Drugs in Clinical Trials for ALS, 2022
Table 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028
Table 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028
Table 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028
Table 17 : Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028
Table 18 : Latest FDA Approvals for Multiple Sclerosis
Table 19 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028
Table 20 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, Through 2028
Table 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 22 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 23 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 24 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028
Table 25 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028
Table 26 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028
Table 27 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028
Table 28 : ESG Ranking of Major Players,2022
Table 29 : ESG Investments, by Key Players, 2022
Table 30 : ESG Trends, Major Players, 2021
Table 31 : ESG Rankings for Major Companies, 2023
Table 32 : CDP Scope Card for Major Players, 2022
Table 33 : Patent Analysis, by Year, Jan. 2020 to March 2023
Table 34 : Major Companies Patents: 2022 to March 2023
Table 35 : M&A: Pharmaceutical Companies
Table 36 : Abbott Laboratories: Annual Revenue, 2022
Table 37 : Abbott Laboratories: News
Table 38 : Abbott Laboratories.: Product Portfolio
Table 39 : Acorda Therapeutics Inc.: News
Table 40 : Acorda Therapeutics Inc.: Product Portfolio
Table 41 : Eli Lily and Company: Annual Revenue, 2022
Table 42 : Eli Lily and Company: News
Table 43 : Eli Lily and Company: Product Portfolio
Table 44 : GlaxoSmithKline PLC: Annual Revenue, 2022
Table 45 : GlaxoSmithKline PLC: News
Table 46 : GlaxoSmithKline PLC: Product Portfolio
Table 47 : Glenmark Life Sciences: Annual Revenue, 2022
Table 48 : Glenmark Life Sciences: Product Portfolio
Table 49 : Novartis AG: Annual Revenue, 2022
Table 50 : Novartis AG: News
Table 51 : Novartis AG: Product Portfolio
Table 52 : Pfizer Inc.: Annual Revenue, 2022
Table 53 : Pfizer Inc.: News
Table 54 : Pfizer Inc.: Product Portfolio
Table 55 : Roche Holding Ltd.: Annual Revenue, 2022
Table 56 : Roche Holding Ltd.: News
Table 57 : Roche Holding Ltd.: Product Portfolio
Table 58 : Sanofi: Annual Revenue, 2022
Table 59 : Sanofi: News
Table 60 : Sanofi: Product Portfolio
Table 61 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
Table 62 : Takeda Pharmaceutical Co. Ltd.: News
Table 63 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 64 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
Table 65 : Teva Pharmaceutical Industries LTD.: Product Portfolio
Table 66 : Abbreviations
List of Figures
Summary Figure A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Summary Figure B : Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028
Figure 1 : Share of Global Health Expenditure Database, 2022
Figure 2 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028
Figure 3 : Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022
Figure 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028
Figure 5 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022
Figure 6 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 7 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 8 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 9 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028
Figure 10 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022
Figure 11 : Global Market for Friedreich's Ataxia Drugs, by Region, 2020-2028
Figure 12 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028
Figure 13 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028
Figure 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028
Figure 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028
Figure 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028
Figure 17 : Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028
Figure 18 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028
Figure 19 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028
Figure 20 : Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022
Figure 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 22 : U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028
Figure 23 : Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 24 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 25 : UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 26 : German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 27 : French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 28 : Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 29 : Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 30 : Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 31 : Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 32 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 33 : Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 34 : Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 35 : Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 36 : Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 37 : Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 38 : Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 39 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028
Figure 40 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028
Figure 41 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028
Figure 42 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028
Figure 43 : Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders
Figure 44 : Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market
Figure 45 : How A Strong ESG Proposition Benefits Pharmaceutical Business
Figure 46 : Share of ESG-Geographical Adoption Level Across All Industries, 2022
Figure 47 : Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023
Figure 48 : Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022
Figure 49 : Abbott Laboratories: Annual Revenue, 2021 and 2022
Figure 50 : Abbott Laboratories: Revenue Shares, by Business Unit, 2022
Figure 51 : Abbott Laboratories.: Revenue Shares, by Region/Country, 2022
Figure 52 : Eli Lily and Company: Annual Revenue, 2021 and 2022
Figure 53 : Eli Lily and Company: Revenue Shares, by Business Unit, 2022
Figure 54 : Eli Lily and Company: Revenue Shares, by Region/Country, 2022
Figure 55 : GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022
Figure 56 : GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022
Figure 57 : GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022
Figure 58 : Glenmark Life Sciences: Annual Revenue, 2021 and 2022
Figure 59 : Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022
Figure 60 : Novartis AG: Annual Revenue, 2021 and 2022
Figure 61 : Novartis AG: Revenue Shares, by Business Unit, 2022
Figure 62 : Novartis AG: Revenue Shares, by Region, 2022
Figure 63 : Pfizer Inc.: Annual Revenue, 2021 and 2022
Figure 64 : Pfizer Inc.: Revenue Shares, by Business Unit, 2022
Figure 65 : Pfizer Inc.: Revenue Shares, by Region/Country, 2022
Figure 66 : Roche Holding Ltd.: Annual Revenue, 2021 and 2022
Figure 67 : Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022
Figure 68 : Roche Holding Ltd.: Revenue Shares, by Region, 2022
Figure 69 : Sanofi: Annual Revenue, 2021 and 2022
Figure 70 : Sanofi: Revenue Shares, by Business Unit, 2022
Figure 71 : Sanofi: Revenue Shares, by Region/Country, 2022
Figure 72 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022
Figure 73 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022
Figure 74 : Takeda Pharmaceutical Company Limited: Revenue Shares, by Region/Country, 2022
Figure 75 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022
Figure 76 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit, 2022
Figure 77 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security